The Ananta Medicare plant (Sriganganagar, Rajasthan, India), manufacturing Cephalosporins in the form of powders for injection, was launched in 2020. The plant complies with international GMP standards. Several international inspections have confirmed this compliance.
Currently, the cephalosporin plant has the following GMP certifications:
- EU GMP (Portugal)
- PIC/S GMP (Ukraine and Thailand)
- Philippines GMP
- Manufacturing Site Registration Certificate (UAE)
- WHO GMP (India)
The plant area is 15000 m2.
Production capacity: 60 mln vials per year.
The product range includes:
|
No. |
Product |
|
1 |
Ceftriaxone For Injection USP 1 g; 2 g |
|
2 |
Cefepime For Injection USP 1 g; 2 g |
|
3 |
Ceftazidime For Injection USP 1 g; 2 g |
|
4 |
Cefotaxime For Injection USP 1 g; 2 g |
|
5 |
Cefoperazone For Injection USP 1 g; 2 g |
|
6 |
Cefuroxime For Injection USP 750 mg; 1.5 g |
|
7 |
Cefazoline For Injection USP 1 g |
|
9 |
Ceftriaxone and Sulbactam For Injection USP 1.5 g |
|
10 |
Cefoperazone and Sulbactam For Injection USP 1.5 g |
|
11 |
Ceftriaxone and Tazobactam Sodium For Injection USP 1.125 g |
